hVIVO - Positive topline results from client Phase 2b field study

hVIVO's Chief Scientific Officer, Dr Andrew Catchpole, discusses Cidara Therapeutics positive topline results from their Phase 2b field study, for which hVIVO recruited participants and performed the virology and immunology laboratory services. The study was to determine the efficacy of Cidara's drug-Fc conjugate, CD388, which is designed as a non-vaccine preventative of seasonal influenza.

Dr. Andrew Catchpole
Chief Scientific Officer, hVIVO

Company Events - HVIVO PLC